Clinical Trial

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Staff April 25, 2023

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

Staff April 25, 2023

Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader (KOL) Larry Ereshefsky, PharmD, BCPP,...

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

Staff April 25, 2023

On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial being conducted in Australia, with...

Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures

Staff April 25, 2023

-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI)...

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

Staff April 25, 2023

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...

Route 92 Medical Receives the First FDA Clearance for a Complete Stroke Treatment System

Staff April 24, 2023

The FreeClimb 70 Reperfusion System, powered by the Tenzing 7 delivery catheter, enables neurointerventionalists to address critical unmet needs in...

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

Staff April 24, 2023

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023...

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

Staff April 24, 2023

IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet...

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE’s Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Staff April 24, 2023

First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has...

Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

Staff April 24, 2023

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

Staff April 23, 2023

Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed...

Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023

Staff April 21, 2023

Data accepted as AAN Late-Breaking AbstractTHE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today...

LianBio Promotes Pascal Qian to Chief Commercial Officer

Staff April 21, 2023

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing...

CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

Staff April 21, 2023

NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and...

Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

Staff April 21, 2023

Seasoned operating executive with successful track record at late-stage biopharmaceutical companiesFARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire...

LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy

Staff April 21, 2023

SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing...

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

Staff April 21, 2023

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

Staff April 21, 2023

Applications are under review in Canada, Australia, the United Kingdom, and SwitzerlandApproval decisions expected in the first half of 2024WALTHAM,...

Freeline Announces Proposed ADS Ratio Change

Staff April 21, 2023

LONDON, April 21, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it plans to change...

Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023

Staff April 21, 2023

Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31,...

Clinical Trial

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

Route 92 Medical Receives the First FDA Clearance for a Complete Stroke Treatment System

INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE’s Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023

LianBio Promotes Pascal Qian to Chief Commercial Officer

CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer

LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

Freeline Announces Proposed ADS Ratio Change

Pixium Vision announces its consolidated financial statements for the financial year 2022 and the consolidated cash balance for March 31, 2023

Casect Launches AI-Enhanced Case Log Platform for Surgeons

CorVel Announces Effectiveness of Three-For-One Forward Stock Split

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Best Testosterone Supplement For Men Over 40 and 50: Testo Prime for Muscle Growth & Libido 2025

The Anxiety Clinic Launches Innovative Approach to Transform Anxiety into Positive Energy

You may have missed